https://pharminent.com/oncology/oncology-intelligence-digest-june-2-2026/ 2026-06-03T00:15:58Z Pharminent en Oncology Intelligence Digest • June 2, 2026 2026-06-03T00:14:46Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-2-2026/ 2026-06-02T21:11:07Z Pharminent en Strategic News Watch • June 2, 2026 2026-06-02T21:11:03Z Blog https://pharminent.com/eli-lilly-issues-data-sharing-ultimatum-to-340b-hospitals/ 2026-06-03T00:23:17Z Pharminent en Eli Lilly issues data sharing ultimatum to 340B hospitals 2026-06-02T17:07:00Z Blog https://pharminent.com/fulcrum-exploring-a-potential-sale-after-fda-sidelined-its-sickle-cell-drug/ 2026-06-03T00:23:22Z Pharminent en Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug 2026-06-02T16:08:00Z Blog https://pharminent.com/asco-2026-kelonia-presents-positive-in-vivo-car-t-data-in-multiple-myeloma/ 2026-06-03T00:23:25Z Pharminent en ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma 2026-06-02T15:17:55Z Blog https://pharminent.com/asco26-in-vivo-oncology-approaches-continue-to-show-promise/ 2026-06-03T00:26:38Z Pharminent en ASCO26: In vivo oncology approaches continue to show promise 2026-06-02T14:47:01Z Blog https://pharminent.com/asco-pfizer-scores-in-lung-colorectal-and-prostate-cancer-but-key-readouts-still-to-come/ 2026-06-03T00:23:27Z Pharminent en ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come 2026-06-02T13:29:18Z Blog https://pharminent.com/fda-issues-draft-guidance-to-help-accelerate-cell-and-gene-therapies-for-patients/ 2026-06-03T00:23:29Z Pharminent en FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients 2026-06-02T13:03:59Z Blog https://pharminent.com/abivax-falls-as-safety-worries-cloud-landmark-immune-drug-results/ 2026-06-03T00:23:33Z Pharminent en AbiVax falls as safety worries cloud 'landmark' immune drug results 2026-06-02T12:22:00Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-june-1-2026/ 2026-06-02T00:25:19Z Pharminent en Rare Disease & Gene Therapy Digest • June 1, 2026 2026-06-02T00:25:14Z Blog https://pharminent.com/81388-2/ 2026-06-03T00:21:18Z Pharminent en 2026-06-02T00:20:31Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-1-2026/ 2026-06-01T18:00:47Z Pharminent en Strategic News Watch • June 1, 2026 2026-06-01T18:00:42Z Blog https://pharminent.com/cordenpharma-inks-ambiopharm-buyout-to-continue-peptide-production-expansion/ 2026-06-01T15:26:41Z Pharminent en CordenPharma inks AmbioPharm buyout to continue peptide production expansion 2026-06-01T14:30:25Z Blog https://pharminent.com/servier-wagers-2-65bn-on-edgewise-muscular-dystrophy-drug/ 2026-06-01T15:26:46Z Pharminent en Servier wagers $2.65bn on Edgewise muscular dystrophy drug 2026-06-01T14:26:18Z Blog https://pharminent.com/asco-summit-reached-with-china-lung-data-but-new-climb-begins-to-prove-global-benefit/ 2026-06-01T15:26:49Z Pharminent en ASCO: Summit reached with China lung data but new climb begins to prove global benefit 2026-06-01T13:35:50Z Blog https://pharminent.com/lilly-and-hanmi-sign-1-26bn-licensing-deal-for-sonefpeglutide/ 2026-06-01T15:29:49Z Pharminent en Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide 2026-06-01T09:43:03Z Blog https://pharminent.com/fda-approves-astrazenecas-imfinzi-bcg-combination-for-nmibc-therapy-2/ 2026-06-01T15:26:53Z Pharminent en FDA approves AstraZeneca's Imfinzi-BCG combination for NMIBC therapy 2026-06-01T07:36:34Z Blog https://pharminent.com/81320-2/ 2026-06-02T00:21:00Z Pharminent en 2026-06-01T00:20:32Z Blog